The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of House Bill 4524. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists. We strongly support the language in the bill that allows a pharmacist to substitute an FDA approved “interchangeable biological product”. That language is consistent with the Biologics Price Competition and Innovation Act (BPCIA) which allows a pharmacist to substitute an interchangeable biologic product without the intervention of the health care provider who prescribed the “reference product”.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
